Highest-materiality recent filing
Tarsus Q2 XDEMVY sales $173.9M (+69% YoY); raises FY guidance to $685-705M; acquires Alkeus
XDEMVY net product sales $173.9M in Q2 2026, up >69% YoY; full-year guidance raised to $685-705M.
Tarsus Pharmaceuticals raises $125M in oversubscribed PIPE financing at $56/share
Gross proceeds of ~$125M from sale of 2,098,519 shares at $56.00 and pre-funded warrants for 133,625 shares at $55.9999.
Tarsus to acquire Alkeus for $450M upfront; adds Phase 3 Stargardt drug gildeuretinol
Upfront consideration: $270M cash + $180M in Tarsus stock ($61.38/share); total ~$450M.
Tarsus acquires iRenix Medical for ~$75M upfront; adds late-stage ocular antiseptic IRX-101
Upfront consideration of $75M: $37.5M cash + $37.5M in Tarsus common stock (607,093 shares).
Tarsus Q1 XDEMVY sales $145.4M (+85% YoY); net loss narrows to $7.0M
XDEMVY net product sales $145.4M vs $78.3M YoY; gross margin 94%.
Q4 2025 net product sales $151.7M (Q4 2024: $66.4M); full-year $451.4M; ~400,000 bottles delivered in 2025.
Tarsus appoints former Allergan CEO David Pyott to Board of Directors
Pyott appointed as Class III director effective Feb 18, 2026; term expires at 2026 annual meeting.
Tarsus Q3 2025: XDEMVY sales $118.7M, +147% YoY; net loss narrows to $0.30/share
XDEMVY net sales of $118.7M (Q3 2024: $48.1M); >103,000 bottles delivered to patients.
Tarsus Q2 net product sales $102.7M, up 152% YoY; net loss narrows to $20.3M
Record Q2 net product sales $102.7M (+152% YoY); 91,000 bottles distributed.
Tarsus Q1 2025: XDEMVY sales $78.3M, up 217% YoY; net loss narrows to $25.1M
Net product sales of XDEMVY $78.3M, up 217% vs Q1 2024 and 18% vs Q4 2024; ~72,000 bottles dispensed.
Tarsus closes public offering of 3.23M shares; net proceeds $134.8M
Underwriters exercised full over-allotment; total shares sold: 3,230,336 (incl. 421,348 additional shares).
Tarsus prices upsized $125M public offering of 2.8M shares at $44.50/share
Offering of 2,808,988 shares at public price $44.50; net proceeds ~$117.1M.
Tarsus Q4 XDEMVY sales $66.4M; full-year $180.1M; net loss narrows to $0.60/share
Q4 net product sales $66.4M (vs $13.1M YoY); full-year $180.1M (vs $14.7M), with 163,000 bottles dispensed in 2024.
Tarsus Q3 2024: XDEMVY sales $48.1M, net loss narrows to $23.4M
Net product sales of $48.1M in Q3 2024, up from $1.7M in Q3 2023; over 41,400 bottles delivered.
Tarsus appoints Elizabeth Yeu as CMO; she resigns from board
Dr. Yeu appointed Chief Medical Officer effective Nov 4, 2024; resigned from Board same date.
Tarsus Q2 2024: XDEMVY net sales $40.8M (65% QoQ), net loss $33.3M, gross-to-net improves to 44%
XDEMVY net product sales $40.8M in Q2, up 65% over Q1; year-to-date $65.5M.
Tarsus Q1 2024: XDEMVY sales $24.7M (+89% QoQ), net loss $35.7M, cash $298.5M
Q1 net product sales of XDEMVY $24.7M, up 89% from Q4 2023; ~26,000 bottles delivered (65% increase).
Tarsus secures $200M non-dilutive credit facility from Pharmakon; draws $75M initially
Initial $75M drawn April 19, 2024; used to repay Hercules Capital/SVB debt and for corporate purposes.
Tarsus Pharmaceuticals completes public offering, raising net proceeds of $107.8M
Sold 3,281,250 shares and pre-funded warrants for 312,500 shares at $32.00 public price.
Tarsus prices $100M public offering of common stock and pre-funded warrants at $32/share
Offering consists of 2,812,500 shares common stock at $32.00/share and pre-funded warrants for 312,500 shares at $31.9999 each.
Tarsus Q4 XDEMVY sales $13.1M; positive Phase 2a rosacea data
XDEMVY net product sales $13.1M in Q4, $14.7M total since late-August launch; >17,400 bottles dispensed.
Tarsus announces positive topline Phase 2a results for TP-03 in MGD with Demodex mites
Ersa trial evaluated TP-03 (lotilaner ophthalmic solution, 0.25%) BID or TID for 12 weeks.
Tarsus reports Q3 net loss $39.1M; XDEMVY launch yields $1.7M in 5 weeks
Net product sales of XDEMVY were $1.7M with ~1,700 bottles dispensed in first 5 weeks post-launch.
Tarsus posts Q2 net loss $31.4M, gets FDA nod for XDEMVY, raises $100M
Net loss of $31.4M in Q2 2023 vs $5.7M loss in Q2 2022; no license revenue ($15.3M in prior year).
Tarsus prices $100M public offering of 5.71M shares at $17.50/share
Net proceeds expected to be ~$93.6M after underwriting discounts and offering expenses.
FDA approves Tarsus' XDEMVY (lotilaner) 0.25% for Demodex blepharitis
FDA approved XDEMVY (lotilaner ophthalmic solution) 0.25% for treatment of Demodex blepharitis.
Tarsus Q1 net loss $23.4M; cash $201.2M; TP-03 PDUFA Aug 25
Net loss of $23.4M vs $20.2M in Q1 2022; revenue $2.5M from LianBio partnership.
Tarsus Pharma appoints Jeff Farrow as CFO and Chief Strategy Officer; Leo Greenstein departs
Leo Greenstein left as CFO effective April 24, 2023; employment continues through June 15, 2023.
Tarsus reports FY2022 net loss of $62.1M; PDUFA for TP-03 on Aug 25, 2023
Full-year net loss $62.1M vs $13.8M in 2021; revenue from TP-03 out-license was $25.8M.
Tarsus extends $25M second tranche draw to March 2024, reduces interest rate on credit facility
Second tranche of $25M under loan agreement: draw period extended to March 15, 2024; minimum $5M drawn by March 15, 2023 and another $5M by Sept 15, 2023.
Tarsus Q3 net loss $22.5M; NDA accepted for TP-03 with PDUFA Aug 2023
Net loss of $22.5M in Q3 2022 vs $15.7M in Q3 2021; R&D expense $10.9M, G&A $12.0M.
Tarsus expands board to nine, appoints Scott Morrison, plans Chairperson transition
Scott Morrison appointed to Board as Class III director effective Oct 6, 2022, and as Audit Committee Chair.
Tarsus Q2 net loss $5.7M; TP-03 NDA submission for Demodex blepharitis on track
Net loss of $5.7M vs net income of $6.3M in Q2 2021; revenue $15.3M from LianBio partnership.
Tarsus Q1 net loss $20.2M; TP-03 hits all endpoints in Saturn-2 Phase 3
Q1 net loss $20.2M vs net income $10.4M YoY; license revenue $0.5M vs $33.4M.
Tarsus prices upsized $75.6M public offering of 5.6M shares at $13.50/share
Priced 5,600,000 shares of common stock at $13.50 per share for gross proceeds of $75.6M.
On July 13, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Aziz Mottiwala would be leaving his role as the Company’s Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a new opportunity as Chief Executive Officer of a public medical device company.
On January 15, 2025, Rosemary Crane, a member of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of her resignation as a member of the Board and any committees of the Board, effective January 17, 2025.
On November 5, 2024, Tarsus Pharmaceuticals, Inc. (the "Company") announced the appointment of Elizabeth Yeu, M.D. as the Company's Chief Medical Officer, effective as of November 4, 2024 (the "Effective Date").
In connection with the appointment, on November 1, 2024, Dr. Yeu resigned as a member of the Company's board of directors (the "Board") and from the committees of the Board on which she served, each effective as of the Effective Date.
On January 18, 2024, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Jose Trevejo, M.D., Ph.D. would be leaving his role as the Company’s Chief Medical Officer (the “Transition”), effective as of January 18, 2024 (the “Transition Date”), and leaving his employment with the Company on February 17, 2024.
The Company also announced the appointment of Jeff Farrow as the Company’s Chief Financial Officer and Chief Strategy Officer, also effective as of the Transition Date.
On April 24, 2023, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Leo Greenstein would be leaving his role as the Company’s Chief Financial Officer (the “Transition”), effective as of April 24, 2023 (the “Transition Date”) and leaving his employment with the Company on June 15, 2023.
Michael Ackermann, the Chairperson of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of his resignation as the Chairperson and as a member of the Board and any committees of the Board, effective December 2, 2022.
and Wendy Yarno, current member of the Board, as Lead Independent Director, each appointment effective as of December 2, 2022.
expanded the size of the Board from eight to nine directors and appointed Scott Morrison to the Board, effective immediately.
Bobak Azamian, the Company’s Chief Executive Officer and current member of the Board will be appointed as Chairperson of the Board
Wendy Yarno, current member of the Board, will be appointed as Lead Independent Director
Max materiality 0.85 · Median 0.68 · Most common event earnings